Cymbalta is NOT an SSRI
Cymbalta (duloxetine) is a serotonin-norepinephrine reuptake inhibitor (SNRI), not a selective serotonin reuptake inhibitor (SSRI). This is a critical distinction with important clinical implications.
Drug Classification
According to the FDA drug label, duloxetine is officially classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) 1. This dual mechanism of action fundamentally differentiates it from SSRIs, which selectively target only serotonin reuptake.
Mechanism of Action
Duloxetine inhibits the reuptake of both serotonin and norepinephrine in the central nervous system 2, 1. Multiple guidelines consistently classify duloxetine alongside venlafaxine as SNRIs (or SSNRIs), explicitly distinguishing them from the SSRI class 2, 3, 4.
The balanced dual inhibition has been demonstrated in preclinical and clinical studies:
- Duloxetine's ability to block serotonin depletion is comparable to SSRIs like paroxetine
- Its norepinephrine reuptake inhibition is similar to selective NRIs like desipramine
- This dual action occurs at clinically relevant doses 5, 6
Clinical Implications of the Distinction
Why this matters in practice:
Adverse effect profile differs from SSRIs: Duloxetine has slightly higher discontinuation rates due to adverse effects compared to SSRIs as a class (67% increased risk vs SSRIs) 3. The norepinephrine component contributes to blood pressure increases and sustained hypertension not typically seen with SSRIs 4.
Broader therapeutic indications: The dual mechanism provides efficacy beyond depression and anxiety. Duloxetine is FDA-approved for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain 7, 8—indications where SSRIs generally lack approval.
Different monitoring requirements: SNRIs including duloxetine require monitoring of blood pressure and pulse due to noradrenergic effects 4, which is not standard practice with SSRIs.
Common Pitfall
A frequent error is grouping all newer antidepressants together as "SSRIs." While duloxetine shares some properties with SSRIs (serotonin reuptake inhibition, similar warnings for suicidality, serotonin syndrome risk), its norepinephrine activity creates a distinct pharmacological profile that affects both efficacy and tolerability 3.